Literature DB >> 34676790

Skindex-Mini Among Patients With Melanoma Who Have Cutaneous Immunotherapy-Related Adverse Effects.

Howa Yeung1,2, Krittin J Supapannachart1, Emily F Cole1, Suephy C Chen3,4.   

Abstract

Entities:  

Keywords:  Skindex-mini; immunotherapy; itch; melanoma; quality of life

Mesh：

Year:  2021        PMID： 34676790      PMCID： PMC8957491          DOI： 10.1177/12034754211051239

Source DB:  PubMed          Journal:  J Cutan Med Surg        ISSN： 1203-4754            Impact factor:   2.092


× No keyword cloud information.
  5 in total

1.  Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases.

Authors:  M M Chren; R J Lasek; A P Sahay; L P Sands
Journal:  J Cutan Med Surg       Date:  2001-03-21       Impact factor: 2.092

2.  The Skindex-Mini: A streamlined quality of life measurement tool suitable for routine use in clinic.

Authors:  Robert A Swerlick; Chao Zhang; Aakash Patel; Mary Margaret Chren; Suephy Chen
Journal:  J Am Acad Dermatol       Date:  2018-12-25       Impact factor: 11.527

3.  Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma.

Authors:  Mario Sznol; Pier Francesco Ferrucci; David Hogg; Michael B Atkins; Pascal Wolter; Massimo Guidoboni; Celeste Lebbé; John M Kirkwood; Jacob Schachter; Gregory A Daniels; Jessica Hassel; Jonathan Cebon; Winald Gerritsen; Victoria Atkinson; Luc Thomas; John McCaffrey; Derek Power; Dana Walker; Rafia Bhore; Joel Jiang; F Stephen Hodi; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2017-09-15       Impact factor: 44.544

4.  The measurement of observer agreement for categorical data.

Authors:  J R Landis; G G Koch
Journal:  Biometrics       Date:  1977-03       Impact factor: 2.571

Review 5.  Cutaneous Adverse Events of Immune Checkpoint Inhibitors: A Summarized Overview.

Authors:  Kerasia-Maria Plachouri; Eleftheria Vryzaki; Sophia Georgiou
Journal:  Curr Drug Saf       Date:  2019
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.